Catheter-directed thrombolysis for thromboembolic disease during pregnancy: a viable option.
Anticoagulation with intravenous heparin has been the standard treatment for the management of gestational thromboembolic complications. Catheter-directed thrombolysis is an encouraging approach for the treatment of thromboembolic disease and has not been previously reported during pregnancy. One gravid woman with pulmonary embolism, critically ill, and hemodynamically compromised, and two gravid women with iliofemoral venous thrombosis, who failed to respond to standard treatment with intravenous heparin, were treated with catheter-directed urokinase. All three patients experienced rapid resolution of symptoms and successful pregnancy outcomes. In our three patients, catheter-directed thrombolysis for thromboembolic disease during pregnancy allowed rapid resolution of hemodynamic abnormalities and/or resolution of thrombus. Catheter-directed thrombolysis offered a reasonably safe alternative to prolonged medical management in these young, otherwise healthy, patients. Long-term, it may prevent the postphlebitic syndrome.
Department of Obstetrics, University of Wisconsin-Madison, 53715, USA.
P
P
Krishnamurthy
C B
CB
Martin
H H
HH
Kay
J
J
Diesner
R O
RO
Friday
C A
CA
Weber
S
S
Droste
D000328:Adult; D002406:Catheterization, Peripheral; D005260:Female; D005268:Femoral Vein; D006801:Humans; D007084:Iliac Vein; D010960:Plasminogen Activators / Q000627:therapeutic use*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011655:Pulmonary Embolism / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000188:drug therapy*
D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator